These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 481551)

  • 21. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats.
    Jafari-Sabet M
    Behav Brain Res; 2006 Apr; 169(1):120-7. PubMed ID: 16443290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of physostigmine on individual phases of learning in man.
    Slánská J; Vojtĕchovský M; Votava Z
    Act Nerv Super (Praha); 1972; 14(2):110-1. PubMed ID: 5040149
    [No Abstract]   [Full Text] [Related]  

  • 23. Memory and cognitive function in the elderly. A preliminary trial of physostigmine.
    Drachman DA; Sahakian BJ
    Arch Neurol; 1980 Oct; 37(10):674-5. PubMed ID: 7425896
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of physostigmine and atropine on some behavioral and electrophysiological functions in rats.
    Bures J
    Prog Brain Res; 1968; 28():61-72. PubMed ID: 5699592
    [No Abstract]   [Full Text] [Related]  

  • 25. Physostigmine: effects on cognition and affect in normal subjects.
    Davis KL; Hollister LE; Overall J; Johnson A; Train K
    Psychopharmacology (Berl); 1976 Dec; 51(1):23-7. PubMed ID: 827772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outpatient treatment of senile dementia with oral physostigmine.
    Beller SA; Overall JE; Rhoades HM; Swann AC
    J Clin Psychiatry; 1988 Oct; 49(10):400-4. PubMed ID: 3049561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A change in the duration of acquired habit retention following "disruption" of dissociated states].
    Azarashvili AA
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1974; 24(6):1189-95. PubMed ID: 4476960
    [No Abstract]   [Full Text] [Related]  

  • 28. Reversal of postoperative reactions to scopolamine with physostigmine.
    Holzgrafe RE; Vondrell JJ; Mintz SM
    Anesth Analg; 1973; 52(6):921-5. PubMed ID: 4796567
    [No Abstract]   [Full Text] [Related]  

  • 29. Cholinergic enhancement and increased selectivity of perceptual processing during working memory.
    Furey ML; Pietrini P; Haxby JV
    Science; 2000 Dec; 290(5500):2315-9. PubMed ID: 11125148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of physostigmine on memory test performance in normal volunteers.
    Smith CM; Coogan JS; Hart S
    Psychopharmacology (Berl); 1986; 90(3):364-6. PubMed ID: 3097725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs.
    Ogura H; Aigner TG
    J Pharmacol Exp Ther; 1993 Jul; 266(1):60-4. PubMed ID: 8331575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of fordine on learning and memory in rats].
    Chen SM; Xue ZG
    Yao Xue Xue Bao; 1987 Nov; 22(11):801-6. PubMed ID: 3452958
    [No Abstract]   [Full Text] [Related]  

  • 33. Modulation of morphine state-dependent learning by muscarinic cholinergic receptors of the ventral tegmental area.
    Darbandi N; Rezayof A; Zarrindast MR
    Physiol Behav; 2008 Jul; 94(4):604-10. PubMed ID: 18479719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Physostigmine antagonizes benzodiazepine-induced amnesia in mice].
    Rektor I; Venault P; Chapouthier G
    Cesk Fysiol; 1988; 37(2):183-6. PubMed ID: 3396091
    [No Abstract]   [Full Text] [Related]  

  • 35. Complementary Modular Microcircuits of the Rat Medial Entorhinal Cortex.
    Ray S; Burgalossi A; Brecht M; Naumann RK
    Front Syst Neurosci; 2017; 11():20. PubMed ID: 28443003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memory-enhancing activity of palmatine in mice using elevated plus maze and morris water maze.
    Dhingra D; Kumar V
    Adv Pharmacol Sci; 2012; 2012():357368. PubMed ID: 23193393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's therapeutics: translation of preclinical science to clinical drug development.
    Savonenko AV; Melnikova T; Hiatt A; Li T; Worley PF; Troncoso JC; Wong PC; Price DL
    Neuropsychopharmacology; 2012 Jan; 37(1):261-77. PubMed ID: 21937983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps.
    Bartus RT; Dean RL
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):15-36. PubMed ID: 19011839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormesis and medicine.
    Calabrese EJ
    Br J Clin Pharmacol; 2008 Nov; 66(5):594-617. PubMed ID: 18662293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physostigmine for Alzheimer's disease.
    Coelho F; Birks J
    Cochrane Database Syst Rev; 2001; 2001(2):CD001499. PubMed ID: 11405996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.